Nov 11, 2009 - The European Commission grants Orphan Drug designation for NGR-hTNF in the treatment of hepatocellular carcinoma

Nov 9, 2009 - MolMed Board of Directors approves the interim financial report as of 30 September 2009

Oct 22, 2009 - MolMed wins the patent litigation related to the TK therapy

Oct 12, 2009 - The US Food and Drug Administration grants Orphan Drug designation of NGR-hTNF for treatment of liver cancer

Sept 24, 2009 - Update of five clinical trials of NGR-hTNF, MolMed’s anticancer investigational biologic drug, presented at ECCO-ESMO 2009

Aug 27, 2009 - MolMed Board of Directors approves the financial report for the first half of year 2009

Jul 30, 2009 - Resignation of Director

Jul 6, 2009 - Silvio Bianchi Martini appointed as independent Member of the Board of Directors of MolMed S.p.A.

Jun 1, 2009 - Clinical update of NGR-hTNF presented at ASCO 2009: Top-line results of Phase II trial in mesothelioma - Combination with cisplatin entering Phase II in lung cancer - Long-term data of Phase II trial in colorectal cancer - Interim update of Phase II trial in liver cancer

May 11, 2009 - MolMed Board of Directors approves the financial report for the first quarter of year 2009

Apr 14, 2009 - MolMed Shareholders Meeting approves Statutory Financial Statements 2008 - Modification of the Corporate Bylaws concerning the stock option plan approved

Apr 2, 2009 - Results of Phase I/II trial of MolMed TK therapy in high risk acute leukaemia published in The Lancet Oncology

Mar 9, 2009 - MolMed Board of Directors reviews the draft financial statements for year 2008

Mar 4, 2009 - European patent granted for MolMed's vascular targeting agent NGR-hTNF

Feb 6, 2009 - MolMed vascular targeting agent NGR-hTNF for solid tumours selected for oral presentation at ANGIO 2009

ARCHIVE

| 2010 | 2009 | 2008 | 2007 | 2005 |